|
1
|
Bosman FT, Carneiro F, Hruban RH and
Theise ND: WHO Classification of Tumours of the Digestive System.
3. 4th edition. WHO Press; Lyon; 2010
|
|
2
|
Zhang Y: Epidemiology of esophageal
cancer. World J Gastroenterol. 19:5598–5606. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pennathur A, Gibson MK, Jobe BA and
Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pennathur A and Luketich JD: Resection for
esophageal cancer: Strategies for optimal management. Ann Thorac
Surg. 85:S751–S756. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vallböhmer D, Brabender J, Metzger R and
Hölscher AH: Genetics in the pathogenesis of esophageal cancer:
Possible predictive and prognostic factors. J Gastrointest Surg.
14(Suppl 1): S75–S80. 2010. View Article : Google Scholar
|
|
6
|
Agrawal N, Jiao Y, Bettegowda C, Hutfless
SM, Wang Y, David S, Cheng Y, Twaddell WS, Latt NL, Shin EJ, et al:
Comparative genomic analysis of esophageal adenocarcinoma and
squamous cell carcinoma. Cancer Discov. 2:899–905. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gibson MK, Abraham SC, Wu TT, Burtness B,
Heitmiller RF, Heath E and Forastiere A: Epidermal growth factor
receptor, p53 mutation, and pathological response predict survival
in patients with locally advanced esophageal cancer treated with
preoperative chemoradiotherapy. Clin Cancer Res. 9:6461–6468.
2003.PubMed/NCBI
|
|
8
|
Makino T, Yamasaki M, Miyata H, Yoshioka
S, Takiguchi S, Fujiwara Y, Nakajima K, Nishida T, Mori M and Doki
Y: p53 mutation status predicts pathological response to
chemoradiotherapy in locally advanced esophageal cancer. Ann Surg
Oncol. 17:804–811. 2010. View Article : Google Scholar
|
|
9
|
Egashira A, Morita M, Yoshida R, Saeki H,
Oki E, Sadanaga N, Kakeji Y, Tsujitani S and Maehara Y: Loss of p53
in esophageal squamous cell carcinoma and the correlation with
survival: Analyses of gene mutations, protein expression, and loss
of heterozygosity in Japanese patients. J Surg Oncol. 104:169–175.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Silveira AP, Da Silva Manoel-Caetano F,
Aoki S, Yamasaki LH, Rahal P and Silva AE: Gene mutations and
polymorphisms of TP53 and FHIT in chronic esophagitis and
esophageal carcinoma. Anticancer Res. 31:1685–1690. 2011.PubMed/NCBI
|
|
11
|
Sengpiel C, König IR, Rades D, Noack F,
Duchrow M, Schild SE, Ludwig D and Homann N: p53 Mutations in
carcinoma of the esophagus and gastroesophageal junction. Cancer
Invest. 27:96–104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Forslund A, Zeng Z, Qin LX, Rosenberg S,
Ndubuisi M, Pincas H, Gerald W, Notterman DA, Barany F and Paty PB:
MDM2 gene amplification is correlated to tumor progression but not
to the presence of SNP309 or TP53 mutational status in primary
colorectal cancers. Mol Cancer Res. 6:205–211. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen B, Cao L, Hu KW, Zhang JW, Meng XL
and Xiong MM: MDM2 SNP309 is an ethnicity-dependent risk factor for
digestive tract cancers. Tumour Biol. 35:3431–3438. 2014.
View Article : Google Scholar
|
|
14
|
Nag S, Zhang X, Srivenugopal KS, Wang MH,
Wang W and Zhang R: Targeting MDM2-p53 interaction for cancer
therapy: Are we there yet? Curr Med Chem. 21:553–574. 2014.
View Article : Google Scholar
|
|
15
|
Bollschweiler E, Hölscher AH and Metzger
R: Histologic tumor type and the rate of complete response after
neoadjuvant therapy for esophageal cancer. Future Oncol. 6:25–35.
2010. View Article : Google Scholar
|
|
16
|
Schneider PM, Baldus SE, Metzger R, Kocher
M, Bongartz R, Bollschweiler E, Schaefer H, Thiele J, Dienes HP,
Mueller RP, et al: Histomorphologic tumor regression and lymph node
metastases determine prognosis following neoadjuvant
radiochemotherapy for esophageal cancer: Implications for response
classification. Ann Surg. 242:684–692. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sobin L, Gospodarowicz M and Wittekind C:
TNM Classification of Malignant Tumours. 7th edition.
Wiley-Blackwell; 2009
|
|
18
|
Merkelbach-Bruse S, Dietmaier W, Füzesi L,
Gaumann A, Haller F, Kitz J, Krohn A, Mechtersheimer G, Penzel R,
Schildhaus HU, et al: Pitfalls in mutational testing and reporting
of common KIT and PDGFRA mutations in gastrointestinal stromal
tumors. BMC Med Genet. 11:1062010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Grünewald I, Vollbrecht C, Meinrath J,
Meyer MF, Heukamp LC, Drebber U, Quaas A, Beutner D, Hüttenbrink
KB, Wardelmann E, et al: Targeted next generation sequencing of
parotid gland cancer uncovers genetic heterogeneity. Oncotarget.
6:18224–18237. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Leach FS, Tokino T, Meltzer P, Burrell M,
Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW and Vogelstein
B: p53 mutation and MDM2 amplification in human soft tissue
sarcomas. Cancer Res. 53:2231–2234. 1993.PubMed/NCBI
|
|
21
|
Higashiyama M, Doi O, Kodama K, Yokouchi
H, Kasugai T, Ishiguro S, Takami K, Nakayama T and Nishisho I: MDM2
gene amplification and expression in non-small cell lung cancer:
Immunohistochemical expression of its protein is a favourable
prognostic marker in patients without p53 protein accumulation. Br
J Cancer. 75:1302–1308. 1997. View Article : Google Scholar
|
|
22
|
Marchetti A, Buttitta F, Pellegrini S,
Merlo G, Chella A, Angeletti CA and Bevilacqua G: MDM2 gene
amplification and overexpression in non-small cell lung carcinomas
with accumulation of the p53 protein in the absence of p53 gene
mutations. Diagn Mol Pathol. 4:93–97. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao Y, Aguilar A, Bernard D and Wang S:
Small-molecule inhibitors of the MDM2-p53 protein-protein
interaction (MDM2 inhibitors) in clinical trials for cancer
treatment. J Med Chem. 58:1038–1052. 2015. View Article : Google Scholar :
|
|
24
|
Tanière P, Martel-Planche G, Puttawibul P,
Casson A, Montesano R, Chanvitan A and Hainaut P: TP53 mutations
and MDM2 gene amplification in squamous-cell carcinomas of the
esophagus in south Thailand. Int J Cancer. 88:223–227. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tanière P, Martel-Planche G, Maurici D,
Lombard-Bohas C, Scoazec JY, Montesano R, Berger F and Hainaut P:
Molecular and clinical differences between adenocarcinomas of the
esophagus and of the gastric cardia. Am J Pathol. 158:33–40. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen B, Xiong MM and Meng XL: Current
evidence on the relationship between murine double minute 2 T309G
polymorphism and esophageal cancer susceptibility. Dis Esophagus.
28:593–601. 2015. View Article : Google Scholar
|
|
27
|
Renouf DJ, Zhai R, Sun B, Xu W, Cheung WY,
Heist RS, Kulke MH, Cescon D, Asomaning K, Marshall AL, et al:
Association of MDM2 T309G and p53 Arg72Pro polymorphisms and
gastroesophageal reflux disease with survival in esophageal
adenocarcinoma. J Gastroenterol Hepatol. 28:1482–1488. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hsu HS, Chen HW, Kao CL, Wu ML, Li AF and
Cheng TH: MDM2 is overexpressed and regulated by the eukaryotic
translation initiation factor 4E (eIF4E) in human squamous cell
carcinoma of esophagus. Ann Surg Oncol. 18:1469–1477. 2011.
View Article : Google Scholar
|
|
29
|
Soslow RA, Altorki NK, Yang G, Xie D and
Yang CS: mdm-2 expression correlates with wild-type p53 status in
esophageal adenocarcinoma. Mod Pathol. 12:580–586. 1999.PubMed/NCBI
|
